Zimmer Biomet Receives Dual Analyst Endorsements Ahead of Earnings

A pair of significant analyst upgrades have generated renewed optimism for Zimmer Biomet Holdings, Inc., marking a potential turning point for the medical technology company after a challenging period. Two prominent financial institutions have issued bullish recommendations just days before the company’s upcoming quarterly earnings release.

Significant Price Target Revisions

The most notable development came from Rothschild & Co Redburn, which not only initiated coverage on Zimmer Biomet with a “Buy” rating but followed with an upgrade to “Strong Buy” just one day later. The firm established a price target of $130 per share, indicating potential upside exceeding 30 percent from recent trading levels. Analysts cited the company’s strategic positioning and its potential to accelerate organic growth rates while reversing historical market share losses.

In a parallel move, Stifel Nicolaus increased its price objective from $115 to $118 while maintaining its “Buy” recommendation. This dual endorsement from respected research firms has overshadowed more cautious perspectives, including UBS’s maintained “Sell” rating despite a modest target price adjustment.

Strong Quarterly Performance Underpins Confidence

The sudden analyst enthusiasm follows Zimmer Biomet’s impressive second-quarter 2025 results reported in August. The company delivered earnings and revenue figures that substantially exceeded market expectations. Adjusted earnings per share reached $2.07, surpassing the $1.98 consensus estimate, while revenue grew 7 percent year-over-year to $2.08 billion, also beating forecasts. Management subsequently raised full-year guidance, demonstrating increased confidence in their operational outlook.

Should investors sell immediately? Or is it worth buying Zimmer Biomet?

Strategic Focus on Robotic Innovation

A key component of Zimmer Biomet’s growth strategy involves expanding its presence in the surgical robotics segment. The company’s July acquisition of Monogram Technologies for $177 million represents a strategic move to enhance its portfolio with autonomous surgical solutions. Monogram’s AI-driven knee replacement robotics platform received FDA clearance in March 2025 and is expected to be commercialized with Zimmer Biomet implants beginning in 2027.

Additionally, the company’s “Magnificent Seven” product launches—including the Persona OsseoTi cementless knee system, which analysts have classified as best-in-class technology—are positioned to strengthen Zimmer Biomet’s leadership in the global knee and hip reconstruction market.

With the next earnings report scheduled for October 29, investor attention is focused on whether Zimmer Biomet can exceed the $1.88 per share earnings expectation. Another strong performance could validate the recent analyst optimism and potentially mark the beginning of a sustained positive trend for the medical device manufacturer.